2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 260-262
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Bispecific Antibody Therapy, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Study Population, Human
PAPER

103 Preliminary safety and efficacy of glofitamab monotherapy and glofitamab in combination with polatuzumab vedotin in patients with Richter’s transformation (RT)

Christine Ryan, MD, Deborah Stephens, DO2, Yinglu Zhou3, Svitlana Tyekucheva, PhD4, Celeste Carey5, Megan Cravinho6, Mari Kniezewski7, Ijaabo Ali8, Brice Messenger9, Anne Beaven, MD10, Christopher Edward Jensen, MD,MSc11, Arianna Crouse12, Aseel Alsouqi, MD13, Jennifer A. Woyach, MD14, Jarah Allen15, Linda Karina Ibarra Almodovar16, Blair Dykeman, MSc17, Philippe Armand, MD18, Amy Bessnow, MD, MPH19, Austin I Kim, MD20, Ann LaCasce, MD, MMSc21, David C Fisher, MD22, Oreofe Odejide, MD, MPH23, Reid W Merryman, MD24, Nathalie Javidi-Sharifi25, Erin Parry, MD, PhD26, Inhye E Ahn, MD27, Jennifer R. Brown, MD, PhD28, Andres Chang, MD,PhD29, Kerry A. Rogers, MD30, Matthew S Davids, MD, MMSc31
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
10 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
11 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
12 The Ohio State University, Columbus, Ohio, United States
13 The Ohio State University, Columbus, Ohio, United States
14 The Ohio State University, Columbus, Ohio, United States
15 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
16 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
17 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
22 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
23 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
24 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
25 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
26 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
27 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
28 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
29 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
30 The Ohio State University, Columbus, Ohio, United States
31 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Introduction: The prognosis for patients (pts) with chronic lymphocytic leukemia (CLL) who develop RT (transformation to large B-cell lymphoma) remains poor and warrants investigation of novel therapies (tx). Given the efficacy of the CD20xCD3 bispecific antibody glofitamab (glofit) in a phase 1 study (Carlo-Stella et al., Blood Adv, 2026), we hypothesized that glofit would be effective in pts with RT as monotherapy (m) and in combination (combo) with other targeted agents. Here we report initial data from the glofit(m) and glofit + polatuzumab vedotin (pola) arms of an ongoing phase II study (NCT06043674).

Methods: Eligible pts in the glofit(m) arm had either treatment-naïve (TN) or relapsed/refractory (R/R) RT. After 11 pts enrolled, the glofit+pola arm opened to pts with TN RT only, with a 10 pt safety lead-in. For cytokine release syndrome (CRS) mitigation, 1000mg obinutuzumab (obin) was administered on cycle (C) 1, day (D) 1 and C1D7. Glofit was given via step-up dosing with required inpatient administration on C1D8 (2.5mg) and C1D15 (10mg). Glofit 30mg was given on D1 of C2-12. Pola was given on D1 of C2-7. Response was assessed by Lugano criteria, toxicities by CTCAE v5, and CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) by ASTCT. Glofit(m) results were planned to be descriptive. The primary endpoint of the glofit+pola arm is complete response (CR) rate.

Results: As of June 15, 2026, 21 pts were enrolled, with accrual complete in the glofit(m) arm (n=11) and glofit+pola arm safety lead-in (n=10). In the glofit(m) arm, median age was 64 years (range 62-77), 6 (55%) were male, and 6 (55%) had TP53-aberrant CLL. Median number (no.) of prior CLL-directed lines of tx (LOT) was 1 (range 0-4). Nine pts (82%) had R/R RT, with 1 median prior RT-directed LOT (range 1-6; all with prior anthracycline CIT). Six pts were BTK inhibitor (BTKi) exposed. In the glofit+pola arm, median age was 72 years (range 61-80), 4 (40%) were male, and 8 (80%) had TP53-aberrant CLL; median no. of prior CLL-directed LOT was 1 (range 0-13) with 5 pts BTKi exposed.

In 11 glofit(m) safety-evaluable (SE) pts, hematologic (heme) AEs were (all grade [Gr]; Gr3+): anemia (55%; 18%), neutropenia (46%; 36%) [with no febrile neutropenia (FN)], thrombocytopenia (36%; 9%). Common non-heme AEs included alanine aminotransferase (ALT) increased (55%; 18%), fatigue (46%; 0%), and Gr3+ infection: 36%.

In 9 glofit+pola SE pts, heme AEs were anemia (67%; 33%), thrombocytopenia (56%; 33%), neutropenia (22%; 22%) with 22% FN. Common non-heme AEs included ALT increased (67%; 11%), alkaline phosphatase increased (67%; 11%), hypoalbuminemia (56%; 0%), and hypophosphatemia (44%; 0%). Gr3+ infection occurred in 1 pt.

Across both arms, CRS rates were similar and occurred in 11/20 pts (55%): maximum Gr1: 25%; Gr2: 15%; Gr3: 15%. ICANS occurred in 1 pt (Gr1). There were 5 obin infusion-related reactions (all Gr2).

In the glofit(m) arm, the median no. of cycles administered was 5 (range 1-12). 2/11 pts completed 12 cycles of tx. Reasons for early tx discontinuation (d/c) were PD (6 pts), election of alternative tx (CAR-T cell and radiation in 1 pt each), and death due to sepsis (1 pt). Reponses were achieved in 6/11 pts (5 CR, 1 partial response [PR]). Median follow-up is 13.8 months (mos) (range 0.4-19.6). 5/11 pts have died (4 due to PD, 1 due to sepsis). The median PFS, duration of response, and OS are 3.7 mos (95%CI 1.3-NR), 13.3 mos (95%CI 2.8-NR), and 17.8 mos (95%CI 1.4-NR).

In the glofit+pola arm, the median no. of glofit and pola cycles administered to-date is 7 (range 0-12) and 6 (range 0-6). Tx is ongoing for 3 pts and 2 pts completed planned tx. Reasons for early tx d/c were PD (3 pts), election of stem cell transplant (1 pt), and death due to intracranial hemorrhage, unrelated to study tx (1 pt). 6 of 9 pts have responded (4 CR, 2 PR) with 1 pt awaiting first response assessment.

Across both arms, all 4 pts who completed tx remain in CR for RT at 4, 5, 14, and 16 mos post-tx. One pt had CLL relapse.

Conclusion: Glofit has single-agent activity in RT with some durable responses observed; however, frequent early PD provides impetus to identify effective combination partners. Our data suggest that glofit-based tx can be safely administered in pts with RT, though some higher-grade CRS occurred. Enrollment is ongoing to the glofit+pola arm, and in arms investigating glofit + the BTKi pirtobrutinib and glofit + the anti-PD-L1 antibody atezolizumab.

Christine Ryan, MD: AstraZeneca - Honoraria; BeOne Medicines - Research Funding; Genentech - Research Funding; Eli Lilly - Research Funding; Genentech - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)